Immunomodulation in cancer therapeutics

International Immunopharmacology

Volumn 3, Issue 8, 2003, Pages 1105-1119

  Ehrke, M Jane ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cancer; Chemotherapeutic agents; Immunomodulation

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ANTIBODY; BLEOMYCIN; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FAMOTIDINE; FLUOROURACIL; INTERLEUKIN 2; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN C; NITROSOUREA; OKT 4; OKT 8; PICIBANIL; TUMOR NECROSIS FACTOR; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; EXPERIMENT; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOPOTENTIATION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL INFORMATION; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0038307758     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00021-3     Document Type: Conference Paper

References (99)

1. Wiemann B., Starnes C.O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 64:1994;529-564.
2. Cao S., Rustum Y.M. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res. 60(14):2000;3717-3721.
3. Zagozdzon R., Golab J. Immunomodulation by anticancer chemotherapy: more is not always better. [Review] Int. J. Oncol. 18:2001;417-424.
4. Ehrke M.J., Mihich E., Berd D., Mastrangelo M.J. Effects of anticancer drugs on the immune system in man. Semin. Oncol. 16:1989;230-253.
5. Mihich R., Ehrke M.J. Immunomodulation by anticancer drugs. DeVita V. Sr., Hellman S., Rosenberg S.A. Biologic therapy of cancer: principles and practice. 1991;776-786 J.B. Lippincott, Philadelphia.
6. Ehrke M.J., Mihich E. Immunopharmacology of anti-cancer agents. Hadden J.W., Szentivanyi A. Immunopharmacology Reviews. vol. 2:1996;103-128 Plenum, New York.
7. Braun D., Harris J.E. Modulation of the immune response by chemotherapy. Pharmacol. Ther. 14:1981;89-122.
8. Ehrke M.J., Mihich E. Immunological effects of anticancer drugs. Berkarda B., Karrer K., Mathe G. Clinical chemotherapy. Antineoplastic Chemotherapy. vol. III:1984;475-499 Thieme-Stratton Publishers, Stuttgart, Germany.
9. Ehrke M.J., Mihich E. Adriamycin and other anthracyclines. Mitchell M., Fahey J. Clinics in Immunology and Allergy. vol. 4, No. 2:1984;259-277 Saunders, London.
10. Ehrke M.J., Mihich E. Immunoregulation by cancer chemotherapeutic agents. Hadden J.W., Szentivanyi A. The reticuloendothelial system: a comprehensive treatise. Pharmacology. vol. VIII:1985;309-347 Plenum, New York. Chapter 12.
11. Mokyr M.B., Dray S. Interplay between the toxic effects of anticancer drugs and host antitumor immunity in cancer therapy. Cancer Invest. 5:1987;31-38.
12. Kempf R.A., Mitchell M.S. Effects of chemotherapeutic agents on the immune response I. Cancer Invest. 2:1984;459-466.
13. Kempf R.A., Mitchell M.S. Effects of chemotherapeutic agents on the immune response II. Cancer Invest. 3:1985;23-33.
14. Hengst J.D.C., Kempf R.A. Immunomodulation by cyclophosphamide. Mitchell M.S., Fahey J.L. Immune suppression and modulation. Clinics in Immunology and Allergy. vol. 4, No. 2:1984;199-216 Saunders, London.
15. Winkelstein A. Immune suppression resulting from various cytotoxic agents. Mitchell M.S., Fahey J.L. Immune suppression and modulation. Clinics in Immunology and Allergy. vol. 4, No. 2:1984;295-315 Saunders, London.
16. Pawelec G., Schmidt H., Schneider E. Cellular immunological defects of chronic myelogenous leukaemics: partial dependence on busulphan therapy. Cancer Immunol. Immunother. 27:1988;89-94.
17. Morikawa K., Hamada J.-I., Itaya T. Modification of regression of virally xenogenized tumor cells by cyclophosphamide and busulfan. Cancer Immunol. Immunother. 26:1988;18-22.
18. Matheson D.S., Green B., Friedman S.J. Studies on the mechanism of activation of human natural killer function by interferon and inhibition of thymidylate synthesis. Cell. Immunol. 111:1988;118-125.
19. Claessen A.M.E., Valster H., Bril H. Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation. Cancer Immunol. Immunother. 28:1989;131-135.
20. Medzihradsky J.L., Klein C., Elion G.B. Differential interference by azathioprine and 6-mercaptopurine with antibody-mediated immunoregulation: synergism of azathioprine and antibody in the control of an immune response. J. Immunol. 129:1982;145-149.
21. Mihich E., Ehrke M.J., Ishizuka M. Immunomodulation by antibiotics. Mihich E., Sakurai Y. Biological responses in cancer: progress towards potential applications. Immunomodulation by Anticancer Drugs. vol. III:1985;71-93 Plenum, New York.
22. Bodenheimer H. Jr., Charland C., Leith J. Alteration of rat Kupffer cell function following mitomycin C administration. J. Leukoc. Biol. 43:1988;265-270.
23. Ligo M., Sakarai M., Saijo N. Synergistic effect of recombinant interleukin-2 on the inhibition of growth of adenocarcinoma 755 by mitomycin. Cancer Treat. Rep. 71:1987;567-570.
24. Akiyoshi T., Arinaga S., Tsuji H. Augmentation of the generation of cell-mediated cytoxicity in culture by mitomycin C. Cancer Immunol. Immunother. 24:1987;259-262.
25. Spreafico F., Vecchi A. The immunomodulatory activity of certain cancer chemotherapeutic agents. Mihich E., Sakurai Y. Biological responses in cancer. Immunomodulation by Anticancer Drugs. vol. 3:1985;131-154 Plenum, New York.
26. Kleinerman E.S., Zwelling L.A. Effects of cisplatin, bleomycin and DTIC on immune function in vitro and in vivo. Mitchell M.S., Fahey J.L. Immune suppression and modulation. Clinics in Immunology and Allergy. vol. 4, No. 2:1984;279-294 Saunders, London.
27. Schlaefli E., Ehrke M.J., Mihich E. The effects of dichloro-trans-dihydroxy-bis-isopropyl-amine-platinum IV on the primary cell-mediated cytotoxic response. Immunopharmacology. 6:1983;107-122.
28. Bogyo D., Ehrke M.J., Mihich E. Reversal by citrovorum factor of methotrexate-induced suppression of cell-mediated and humoral immune responses in mouse model systems. Biochem. Pharmacol. 31:1982;1387-1392.
29. + cells in murine acute graft versus host reactions. J. Immunol. 142:1989;1867-1873.
30. Matheson D.S., Green B., Hoar D.J. The influence of methotrexate and thymidine on the human natural killer cell function in vitro. J. Immunol. 131:1983;1619-1621.
31. Rosenthal G. Jr., Weigand G.W., Germolec D.R. Suppression of B cell function by methotrexate and trimethotrexate: evidence for inhibition of purine biosynthesis as a major mechanism of action. J. Immunol. 141:1988;410-416.
32. Morikawa K., Hosakawa M., Hamada J. Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin in a rat fibrosarcoma. Cancer Res. 45:1985;1502-1507.
33. Parker D., Turk J.L. Potentiation of T-lymphocyte function by bleomycin. Immunopharmacology. 7:1984;109-113.
34. Abdul Hamiel T.A., Turk J.L. Enhancement of interleukin 2 release in rats by treatment with bleomycin and Adriamycin in vivo. Cancer Immunol. Immunother. 25:1987;245-249.
35. Orsini F., Eppolito C., Ehrke M.J., Mihich E. Effects of selected anticancer agents on the development of primary complement-independent cell mediated immune response against allogeneic tumor cells in culture. Cancer Treat. Rep. 64:1980;211-218.
36. Nagarkatti M., Nagarkatti P.S., Kaplan A.M. Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor. Cancer Immunol. Immunother. 27:1988;38-46.
37. Ehrke M.J., Cohen S.A., Mihich E. Selective effects of Adriamycin on murine host defense systems. Immunol. Rev. 65:1982;54-78.
38. Cohen S.A., Ehrke M.J., Mihich E. Selectivity of immunomodulation by Adriamycin. Weber G. Advances in Enzyme Regulation. vol. 18:1980;335-346 Pergamon, New York.
39. Ehrke M.J., Mihich E. Effects of anticancer agents on immune responses. Trends Pharmacol. Sci. 6:1985;412-417.
40. Ehrke M.J., Tomazic V., Ryoyama K., Cohen S.A., Mihich E. Adriamycin induced immunomodulation: dependence upon time of administration. Int. J. Immunopharmacol. 5:1983;43-48.
41. Carter S.K. Adriamycin - a review. J. Natl. Cancer Inst. 55:1975;1265-1274.
42. Schwartz H.S., Grindey G.B. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res. 33:1973;1837-1844.
43. Schwartz H.S., Kanter P. Cell interactions: determinants of selective toxicity of Adriamycin and daunorubicin. Cancer Chemother. Rep. 6:1975;107-114.
44. Mantovani A., Candiani P., Luini W. Effects of chemotherapeutic agents on host defense mechanisms: its possible relevance for the antitumoral activity of these drugs. Ferrone S., Gorini S., Herberman G.B. Current trends in tumor immunology. 1979;139-154 Garland, New York.
45. Cohen S.A., Ehrke M.J., Ryoyama K., Mihich E. Augmentation of phagocytic activity of murine spleen cell populations induced by Adriamycin. Immunopharmacology. 5:1982;75-84.
46. Mace K., Mayhew E., Mihich E., Ehrke M.J. Alterations in murine host defense functions by Adriamycin or liposome-encapsulated Adriamycin. Cancer Res. 48:1988;130-136.
47. Ehrke M.J., Ryoyama K., Cohen S.A. Cellular basis for Adriamycin-induced augmentation of cell mediated cytotoxicity in culture. Cancer Res. 44:1984;2497-2504.
48. Ehrke M.J., Maccubbin D., Ryoyama K., Cohen S.A., Mihich E. Correlation between Adriamycin-induced augmentation of interleukin 2 production and of cell mediated cytotoxicity. Cancer Res. 46:1986;54-60.
49. Ujhazy P, Zaleskis G, Mihich E, Ehrke MJ, Berleth E. Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells [submitted for publication].
50. Mace K., Mayhew E., Mihich E., Ehrke M.J. Production of a soluble mediator with tumor lytic activity by adherent peritoneal exudate cells from mice treated with Adriamycin or liposome encapsulated Adriamycin. J. Leukoc. Biol. 38:1985;68.
51. Maccubbin D., Cohen S., Ehrke M. Indomethacin modulation of Adriamycin induced effects on multiple cytolytic effector functions. Cancer Immunol. Immunother. 31:1990;373-380.
52. Santoni A., Ricardi C., Sorci V., Herberman R. Effects of Adriamycin on the activity of mouse natural killer cells. J. Immunol. 124:1980;2329-2336.
53. Orsini F., Pavelic Z., Mihich E. Increased primary cell mediated immunity in culture subsequent to Adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res. 37:1977;1719-1726.
54. Tomazic V., Ehrke M.J., Mihich E. Augmentation of the development of immune responses of mice against allogeneic tumor cells after Adriamycin treatment. Cancer Res. 41:1981;3370-3376.
55. Maccubbin D., Wing K., Mace K.F., Ho R.L.X., Ehrke M.J., Mihich E. Adriamycin-modulation of host defenses in tumor-bearing mice. Cancer Res. 52:1992;3572-3576.
56. Zaleskis G., Verstovšek S., Tzai T.-S., Mihich E., Ehrke M.J. Doxorubicin and cyclosporin A affect murine lymphoid cells expressing different antigenic determinants. Oncol. Res. 7:1995;307-316.
57. Faanes R.B., Merluzzi V.J., Ralph P., Williams N., Tarnowski G.S. Restoration of tumor and drug-induced immune dysfunction. Serrou B., Rosenfeld C. International Symposium on New Trends in Human Immunology and Cancer Immunotherapy. 1980;953-964 Doin Editeurs, Paris.
58. Hengst J.C.D., Mokyr M.B., Dray S. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. Cancer Res. 40:1980;2135-2141.
59. Hengst J.C.D., Mokyr M.B., Dray S. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res. 41:1981;2163-2167.
60. Mokyr M.B., Hengst J.C.D., Dray S. The role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous non-palpable MOPC-315 tumors. Cancer Res. 42:1982;974-979.
61. Cowens J.W., Ozer H., Ehrke M.J., Colvin M., Mihich E. Inhibition of the development of suppressor cells in culture by 4-hydroperoxycyclophosphamide. J. Immunol. 132:1983;95-100.
62. Chatenoud L., Salomon B., Bluestone J.A. Suppressor T cells - they're back and critical for regulation of autoimmunity! Immunol. Rev. 182:2001;149-163.
63. Borden E.C., Hawkins M.J. Biologic response modifiers as adjuncts to other therapeutic modalities. Semin. Oncol. 13:1986;144-452.
64. Pearson J.W., Perk K., Chirigos M.A., Pryor J.W., Fuhrman F.S. Histological and combined chemoimmunostimulation therapy studies against a murine leukemia. [Journal article] Int. J. Cancer. 16(1):1975 (Jul. 15);142-152.
65. Taguchi T. Clinical studies on PSK: combination therapy of PSK with surgery and chemotherapy. [Journal article] Recent Results Cancer Res. 68:1978;236-240.
66. Regenass U., Muller M., Curschellas E., Matter A. Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int. J. Cancer. 39:1987;266-273.
67. Salup R.R., Back T.C., Wiltrout R.H. Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy. J. Immunol. 138:1987;641-647.
68. Ho R.L.X., Maccubbin D., Zaleskis G., Krawczyk C., Wing K., Mihich E.et al. Development of a safe and effective Adriamycin plus interleukin 2 therapy against both Adriamycin sensitive and resistant lymphomas. Oncol. Res. 5:1993;373-381.
69. Ho R.L.X., Maccubbin D., Ujházy P., Zaleskis G., Eppolito C., Mihich E.et al. Immunological responses critical to the therapeutic effects of Adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma. Oncol. Res. 5:1993;363-372.
70. Ehrke M.J., Verstovšek S., Ho R.L.X., Ujházy P., Zaleskis G., Maccubbin D.et al. Specific anti-primary EL4 lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol. Immunother. 42:1996;221-230.
71. Luo L., Ewens A., Ehrke M.J., Mihich E. Immunomodulation-dependent therapeutic effects of doxorubicin plus interleukin 2. Proc. AACR. 43:2002;972.
72. North R.J., Dye E.S., Mills C.D. Modulation of antitumor immunity-immunobiologic approaches. Springer Semin. Immunopathol. 5:1982;193-220.
73. North R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 55:1982;1063-1074.
74. Cheever M.A., Greenberg P.D., Fefer A. Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: II. Comparison of cells cultured with and without tumor to noncultured immune cells. J. Immunol. 121:1978;2220-2227.
75. Cheever M.A., Greenberg P.D., Fefer A. Lymphocyte transfer for cancer therapy: prerequisites for efficacy and the use of long-term cultured T lymphocytes. Mihich E. Biological responses in cancer: progress toward potential applications. 1984;145-183 Plenum, New York.
76. Greenberg P.D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:1991;281-355.
77. Krawczyk C.M., Verstovšek S., Ujházy P., Maccubbin D., Ehrke M.J. Protective specific immunity induced by cyclophosphamide plus TNFα combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Cancer Immunol. Immunother. 40:1995;347-357.
78. Ehrke M.J., Verstovšek S., Krawczyk C.M., Ujházy P., Zaleskis G., Maccubbin D.et al. Cyclophosphamide plus tumor necrosis factor-a chemoimmuno-therapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int. J. Cancer. 63:1995;463-471.
79. Ehrke M.J., Verstovšek S., Pocchiari S.K., Krawczyk C.M., Ujházy P., Zaleskis G.et al. Thymic anti-tumor effectors in chemoimmunotherapy cured mice: phenotypic and functional characterization up to 20 months after initial tumor inoculation. Int. J. Cancer. 76:1998;579-586.
80. Polak L., Turk J.L. Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature. 249:1974;654-656.
81. Ehrke M.J. Effect of cancer therapy on host response and immunobiology. Curr. Opin. Oncol. 3:1991;1070-1077.
82. Arinaga S., Akiyoshi T., Tsuji H. Augmentation of the cell-mediated cytotoxic response induced in mixed cell culture by Adriamycin. Jpn. J. Cancer Res. 76:1985;414-419.
83. Arinaga S., Akiyoshi T., Tsuji H. Augmentation of the generation of cell-mediated cytotoxicity after a single dose of Adriamycin in cancer patients. Cancer Res. 46:1986;4213-4216.
84. Berd D., Maguire H.C. Jr., Mastrangelo M.J. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res. 44:1984;5439-5443.
85. Paciucci P.A., Bekesi J.G., Ryder J.S., Odchimar R., Chahinian P.A., Holland J.F. Immunotherapy with IL2 by constant infusion and weekly doxorubicin. Am. J. Clin. Oncol. 16:1991;341-348.
86. Kawata A., Une Y., Hosokawa M., Wakizaka Y., Namieno T., Uchino J.et al. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus Adriamycin alone. Am. J. Clin. Oncol. 18:1995;257-262.
87. Le Cesne A., Vassal G., Farace F., Spielmann M., Le Chevalier T., Angevin E.et al. Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma? J. Immunother. 22:1999;268-277.
88. Clamon G., Herndon J., Perry M.C., Ozer H., Kreisman H., Maher T., Ellerton J., Gree M.R. Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of cancer and Leukemia Group B. J. Natl. Cancer Inst. 85:1993;316-320.
89. Nio Y., Nagami H., Tamura K., Tsubono M., Nio M., Sato M.et al. Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion. Br. J. Cancer. 80:1999;775-785.
90. Yamamoto M., Fujii H. Optimal locoregional immunochemotherapy after tumor-mass reduction for advanced hepatocellular carcinoma. Hepato-Gastroenterology. 42:1995;567-577.
91. Maguire H.C. Jr., Ettore V.L. Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J. Invest. Dermatol. 48:1967;39-42.
92. Berd D., Maguire H.C. Jr., Mastrangelo M.J. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 46:1986;2572-2577.
93. Mitchell M.S. Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and interleukin-2. Semin. Oncol. 19:1992;80-87.
94. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S.et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1994;1159-1166.
95. Barrera J.L., Verastegui E., Meneses A., Zinser J., de la Garza J., Hadden J.W. Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Arch. Otolaryngol. Head Neck Surg. 126:2000;345-351.
96. Hoon D.S., Foshag L.J., Nizze A.S., Bohman R., Morton D.L. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res. 50:1990;5358-5364.
97. Berd D., Maguire H.C. Jr., Schuchter L.M., Hamilton R., Hauck W.W., Sato T.et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J. Clin. Oncol. 15:1997;2359-2370.
98. Berd D., Sato T., Cohn H., Maguire H.C. Jr., Mastrangelo M.J. Treatment of metastatic melanoma with autologous hapten-modified melanoma vaccine: regression of pulmonary metastases. Int. J. Cancer. 94:2001;531-539.
99. Emens L.A., Machiels J.P., Reilly R.T., Jaffee E.M. Chemotherapy: friend or foe to cancer vaccines? Curr. Opin. Mol. Ther. 3:2001;77-84.